October 31, 2024, Beijing Biostar Pharmaceuticals Co., Ltd. (“Biostar”, HKEX: 2563), which is a synthetic biology-driven biopharma company focusing on the development of patented innovative oncology drugs, today listed on the main board of Hong Kong Stock Exchange, making it the first public synthetic pharmaceutical company in Hong Kong.

At the listing ceremony, Dr Li Tang, the Chairman, Executive Director, Chief Scientific Officer, and Chief Marketing Officer of Biostar, and Dr. Rongguo Qiu, Vice Chairman, Executive Director and Chief Executive Officer, rang the opening gong to celebrate the new journey of the company. The company's cornerstone investors, directors and supervisors, shareholders, sponsors and intermediaries of the IPO were present at the listing ceremony, witnessing the milestone moment on the development road of the company.

Dr. Li Tang said in her speech, "As a biopharmaceutical company driven by synthetic biology technology, Biostar is committed to developing innovative oncology drugs. The successful listing is an important milestone in Biostar's development process, and it is also a new beginning. In the future, we will continue to adhere to research and innovation, launch more innovative drug products, and bring our existing products to more patients, making greater contributions to the cause of life and health."